Adverse effects of concentrated green tea extracts

Molecular Nutrition and Food Research

Volumn 55, Issue 6, 2011, Pages 874-885

  Schönthal, Axel H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Boronic acid; Bortezomib; Cis diol; Hepatotoxicity; Liver damage

Indexed keywords

CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; PLANT EXTRACT;

ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DIET SUPPLEMENTATION; DRUG ANTAGONISM; HERB DRUG INTERACTION; HUMAN; KINETICS; LIVER FAILURE; METABOLISM; PHYTOTHERAPY; REVIEW; TEA;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; GLUCURONOSYLTRANSFERASE; HEPATIC INSUFFICIENCY; HERB-DRUG INTERACTIONS; HUMANS; KINETICS; P-GLYCOPROTEIN; PHYTOTHERAPY; PLANT EXTRACTS; TEA;

ANIMALIA;

EID: 79958038182     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201000644     Document Type: Review

References (129)

1. Moore, R. J., Jackson, K. G., Minihane, A. M., Green tea (Camellia sinensis) catechins and vascular function. Br. J. Nutr. 2009, 102, 1790-1802.
2. Sturgeon, J. L., Williams, M., van Servellen, G., Efficacy of green tea in the prevention of cancers. Nurs. Health Sci. 2009, 11, 436-446.
3. Cabrera, C., Artacho, R., Gimenez, R., Beneficial effects of green tea - a review. J. Am. Coll. Nutr. 2006, 25, 79-99.
4. Chacko, S. M., Thambi, P. T., Kuttan, R., Nishigaki, I., Beneficial effects of green tea: a literature review. Chin. Med. 2010, 5, 13.
5. Dulloo, A. G., Duret, C., Rohrer, D., Girardier, L. et al., Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am. J. Clin. Nutr. 1999, 70, 1040-1045.
6. Phung, O. J., Baker, W. L., Matthews, L. J., Lanosa, M. et al., Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. Am. J. Clin. Nutr. 2010, 91, 73-81.
7. Wolfram, S., Wang, Y., Thielecke, F., Anti-obesity effects of green tea: from bedside to bench. Mol. Nutr. Food Res. 2006, 50, 176-187.
8. Hursel, R., Viechtbauer, W., Westerterp-Plantenga, M. S., The effects of green tea on weight loss and weight maintenance: a meta-analysis. Int. J. Obes. 2009, 33, 956-961.
9. Nagao, T., Hase, T., Tokimitsu, I., A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity 2007, 15, 1473-1483.
10. Westerterp-Plantenga, M. S., Green tea catechins, caffeine and body-weight regulation. Physiol. Behav. 2010, 100, 42-46.
11. Sparreboom, A., Cox, M. C., Acharya, M. R., Figg, W. D., Herbal remedies in the United States: potential adverse interactions with anticancer agents. J. Clin. Oncol. 2004, 22, 2489-2503.
12. Richardson, M. A., Sanders, T., Palmer, J. L., Greisinger, A., Singletary, S. E., Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 2000, 18, 2505-2514.
13. Burstein, H. J., Gelber, S., Guadagnoli, E., Weeks, J. C., Use of alternative medicine by women with early-stage breast cancer. N. Engl. J. Med. 1999, 340, 1733-1739.
14. Kennedy, J., Herb and supplement use in the US adult population. Clin. Ther. 2005, 27, 1847-1858.
15. Cooper, R., Morre, D. J., Morre, D. M., Medicinal benefits of green tea: part II. Review of anticancer properties. J. Altern. Complement. Med. 2005, 11, 639-652.
16. Cooper, R., Morre, D. J., Morre, D. M., Medicinal benefits of green tea: part I. Review of noncancer health benefits. J. Altern. Complement. Med. 2005, 11, 521-528.
17. Pastore, R. L., Fratellone, P., Potential health benefits of green tea (Camellia sinensis): a narrative review. Explore 2006, 2, 531-539.
18. Bishnu, A., Chakrabarti, K., Chakraborty, A., Saha, T., Pesticide residue level in tea ecosystems of Hill and Dooars regions of West Bengal, India. Environ. Monit. Assess. 2009, 149, 457-464.
19. Gurusubramanian, G., Rahman, A., Sarmah, M., Ray, S., Bora, S., Pesticide usage pattern in tea ecosystem, their retrospects and alternative measures. J. Environ. Biol. 2008, 29, 813-826.
20. Lin, Y. S., Tsai, Y. J., Tsay, J. S., Lin, J. K., Factors affecting the levels of tea polyphenols and caffeine in tea leaves. J. Agric. Food Chem. 2003, 51, 1864-1873.
21. Khokhar, S., Magnusdottir, S. G., Total phenol, catechin, and caffeine contents of teas commonly consumed in the United kingdom. J. Agric. Food Chem. 2002, 50, 565-570.
22. USDA Nutrient Data Laboratory, USDA Database for the Flavonoid Content of Selected Foods. Release 2.1, Department of Agriculture, Beltsville, MD 2007.
23. Saitu, N., Study on tea drinks, contents of catechins, caffeine, and total amino acid. Report Cons. Sci. Res. Inst. Hyogo Prefecture 1998, 13, 242.
24. Astill, C., Birch, M. R., Dacombe, C., Humphrey, P. G., Martin, P. T., Factors affecting the caffeine and polyphenol contents of black and green tea infusions. J. Agric. Food Chem. 2001, 49, 5340-5347.
25. Gross, G., Meyer, K. G., Pres, H., Thielert, C. et al., A randomized, double-blind, four-arm parallel-group, placebo-controlled phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J. Eur. Acad. Dermatol. Venereol. 2007, 21, 1404-1412.
26. Stockfleth, E., Beti, H., Orasan, R., Grigorian, F. et al., Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br. J. Dermatol. 2008, 158, 1329-1338.
27. Tatti, S., Swinehart, J. M., Thielert, C., Tawfik, H. et al., Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet. Gynecol. 2008, 111, 1371-1379.
28. Zhang, Q., Fu, H., Pan, J., He, J. et al., Effect of dietary Polyphenon E and EGCG on lung tumorigenesis in A/J mice. Pharm. Res. 2010, 27, 1066-1071.
29. Lee, M. J., Wang, Z. Y., Li, H., Chen, L. et al., Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol. Biomarkers Prev. 1995, 4, 393-399.
30. Pietta, P., Simonetti, P., Gardana, C., Brusamolino, A. et al., Relationship between rate and extent of catechin absorption and plasma antioxidant status. Biochem. Mol. Biol. Int. 1998, 46, 895-903.
31. Unno, T., Kondo, K., Itakura, H., Takeo, T., Analysis of (-)-epigallocatechin gallate in human serum obtained after ingesting green tea. Biosci. Biotechnol. Biochem. 1996, 60, 2066-2068.
32. Yang, C. S., Chen, L., Lee, M. J., Balentine, D. et al., Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol. Biomarkers Prev. 1998, 7, 351-354.
33. Pisters, K. M., Newman, R. A., Coldman, B., Shin, D. M. et al., Phase I trial of oral green tea extract in adult patients with solid tumors. J. Clin. Oncol. 2001, 19, 1830-1838.
34. Chung, F. L., Wang, M., Rivenson, A., Iatropoulos, M. J. et al., Inhibition of lung carcinogenesis by black tea in Fischer rats treated with a tobacco-specific carcinogen: caffeine as an important constituent. Cancer Res. 1998, 58, 4096-4101.
35. Lou, Y. R., Lu, Y. P., Xie, J. G., Huang, M. T., Conney, A. H., Effects of oral administration of tea, decaffeinated tea, and caffeine on the formation and growth of tumors in high-risk SKH-1 mice previously treated with ultraviolet B light. Nutr. Cancer 1999, 33, 146-153.
36. Imai, K., Suga, K., Nakachi, K., Cancer-preventive effects of drinking green tea among a Japanese population. Prev. Med. 1997, 26, 769-775.
37. Chow, H. H., Cai, Y., Hakim, I. A., Crowell, J. A. et al., Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 2003, 9, 3312-3319.
38. Chow, H. H., Cai, Y., Alberts, D. S., Hakim, I. et al., Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol. Biomarkers Prev. 2001, 10, 53-58.
39. Ullmann, U., Haller, J., Decourt, J. D., Girault, J. et al., Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. Int. J. Vitam. Nutr. Res. 2004, 74, 269-278.
40. Chow, H. H., Hakim, I. A., Vining, D. R., Crowell, J. A. et al., Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin. Cancer Res. 2005, 11, 4627-4633.
41. Ullmann, U., Haller, J., Decourt, J. P., Girault, N. et al., A single ascending dose study of epigallocatechin gallate in healthy volunteers. J. Int. Med. Res. 2003, 31, 88-101.
42. Isbrucker, R. A., Edwards, J. A., Wolz, E., Davidovich, A., Bausch, J., Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem. Toxicol. 2006, 44, 636-650.
43. Shanafelt, T. D., Call, T. G., Zent, C. S., LaPlant, B. et al., Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J. Clin. Oncol. 2009, 27, 3808-3814.
44. Dara, L., Hewett, J., Lim, J. K., Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J. Gastroenterol. 2008, 14, 6999-7004.
45. Molinari, M., Watt, K. D., Kruszyna, T., Nelson, R. et al., Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl. 2006, 12, 1892-1895.
46. Mazzanti, G., Menniti-Ippolito, F., Moro, P. A., Cassetti, F. et al., Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 2009, 65, 331-341.
47. Javaid, A., Bonkovsky, H. L., Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J. Hepatol. 2006, 45, 334-335; author reply 335-336.
48. Sarma, D. N., Barrett, M. L., Chavez, M. L., Gardiner, P. et al., Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf. 2008, 31, 469-484.
49. Atwater, J., Salguero, J. M., Roll, D. B., The USP Dietary Supplement Verification Program: helping pharmacists and consumers select dietary supplements. US Pharm. 2005, 30, 61-64.
50. Kantelip, J. P., Laroche, D., Green tea and liver disorders. National Drug Surveillance survey submitted to the Technical Committee. Beasancon Regional Drug Surveillance Centre, Besancon, 2003.
51. Stevens, T., Qadri, A., Zein, N. N., Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann. Intern. Med. 2005, 142, 477-478.
52. Lanca, S., Alves, A., Vieira, A. I., Barata, J. et al., Chromium-induced toxic hepatitis. Eur. J. Intern. Med. 2002, 13, 518-520.
53. Chen, J. H., Tipoe, G. L., Liong, E. C., So, H. S. et al., Green tea polyphenols prevent toxin-induced hepatotoxicity in mice by down-regulating inducible nitric oxide-derived prooxidants. Am. J. Clin. Nutr. 2004, 80, 742-751.
54. Dobrzynska, I., Sniecinska, A., Skrzydlewska, E., Figaszewski, Z., Green tea modulation of the biochemical and electric properties of rat liver cells that were affected by ethanol and aging. Cell. Mol. Biol. Lett. 2004, 9, 709-721.
55. Fiorini, R. N., Donovan, J. L., Rodwell, D., Evans, Z. et al., Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice. Liver Transpl. 2005, 11, 298-308.
56. Nishikawa, T., Nakajima, T., Moriguchi, M., Jo, M. et al., A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J. Hepatol. 2006, 44, 1074-1082.
57. Zhen, M. C., Huang, X. H., Wang, Q., Sun, K. et al., Green tea polyphenol epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation. Acta Pharmacol. Sin. 2006, 27, 1600-1607.
58. Bruno, R. S., Dugan, C. E., Smyth, J. A., DiNatale, D. A., Koo, S. I., Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. J. Nutr. 2008, 138, 323-331.
59. Abe, K., Ijiri, M., Suzuki, T., Taguchi, K. et al., Green tea with a high catechin content suppresses inflammatory cytokine expression in the galactosamine-injured rat liver. Biomed. Res. 2005, 26, 187-192.
60. Arteel, G. E., Uesugi, T., Bevan, L. N., Gabele, E. et al., Green tea extract protects against early alcohol-induced liver injury in rats. Biol. Chem. 2002, 383, 663-670.
61. Chan, P., Ramot, Y., Malarkey, D., Blackshear, P. et al., Fourteen-week toxicity study of green tea extract in rats and mice. Toxicol. Pathol. 2010, 38, 1070-1084.
62. Galati, G., Lin, A., Sultan, A. M., O'Brien, P. J., Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic. Biol. Med. 2006, 40, 570-580.
63. Lambert, J. D., Kennett, M. J., Sang, S., Reuhl, K. R. et al., Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem. Toxicol. 2010, 48, 409-416.
64. Schmidt, M., Schmitz, H. J., Baumgart, A., Guedon, D. et al., Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem. Toxicol. 2005, 43, 307-314.
65. Frank, J., George, T. W., Lodge, J. K., Rodriguez-Mateos, A. M. et al., Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. J. Nutr. 2009, 139, 58-62.
66. Jin, X., Zheng, R. H., Li, Y. M., Green tea consumption and liver disease: a systematic review. Liver Int. 2008, 28, 990-996.
67. Ui, A., Kuriyama, S., Kakizaki, M., Sone, T. et al., Green tea consumption and the risk of liver cancer in Japan: the Ohsaki Cohort study. Cancer Causes Control 2009, 20, 1939-1945.
68. Larsson, S. C., Wolk, A., Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007, 132, 1740-1745.
69. Memorial Sloan-Kettering Cancer Center. Green Tea. 2010, .
70. Colalto, C., Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharmacol. Res. 2010, 62, 207-227.
71. Holbrook, A. M., Pereira, J. A., Labiris, R., McDonald, H. et al., Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 2005, 165, 1095-1106.
72. Hu, Z., Yang, X., Ho, P. C., Chan, S. Y. et al., Herb-drug interactions: a literature review. Drugs 2005, 65, 1239-1282.
73. Izzo, A. A., Di Carlo, G., Borrelli, F., Ernst, E., Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int. J. Cardiol. 2005, 98, 1-14.
74. Brinker, F., Contraindications and Drug Interactions, Eclectic Medical Publications, Sandy, OR 2001.
75. Leslie, E. M., Deeley, R. G., Cole, S. P., Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204, 216-237.
76. Jodoin, J., Demeule, M., Beliveau, R., Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta 2002, 1542, 149-159.
77. Zhou, S., Lim, L. Y., Chowbay, B., Herbal modulation of P-glycoprotein. Drug Metab. Rev. 2004, 36, 57-104.
78. Choi, J. S., Burm, J. P., Effects of oral epigallocatechin gallate on the pharmacokinetics of nicardipine in rats. Arch. Pharm. Res. 2009, 32, 1721-1725.
79. Chung, J. H., Choi, D. H., Choi, J. S., Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm. Drug Dispos. 2009, 30, 90-93.
80. Li, C., Choi, J. S., Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats. Pharmazie 2008, 63, 815-818.
81. Liang, G., Tang, A., Lin, X., Li, L. et al., Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int. J. Oncol. 2010, 37, 111-123.
82. Shin, S. C., Choi, J. S., Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs 2009, 20, 584-588.
83. Farabegoli, F., Papi, A., Bartolini, G., Ostan, R., Orlandi, M., (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 2010, 17, 356-362.
84. Mei, Y., Qian, F., Wei, D., Liu, J., Reversal of cancer multidrug resistance by green tea polyphenols. J. Pharm. Pharmacol. 2004, 56, 1307-1314.
85. Qian, F., Wei, D., Zhang, Q., Yang, S., Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Biomed. Pharmacother. 2005, 59, 64-69.
86. Zhang, Q., Wei, D., Liu, J., In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft. Cancer Lett. 2004, 208, 179-186.
87. Kageyama, M., Fukushima, K., Togawa, T., Fujimoto, K. et al., Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol. Pharm. Bull. 2006, 29, 779-784.
88. Tanigawara, Y., Role of P-glycoprotein in drug disposition. Ther. Drug Monit. 2000, 22, 137-140.
89. Lin, L. C., Wang, M. N., Tsai, T. H., Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem. Biol. Interact. 2008, 174, 177-182.
90. Lu, H., Meng, X., Li, C., Sang, S. et al., Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab. Dispos. 2003, 31, 452-461.
91. Chen, L., Lee, M. J., Li, H., Yang, C. S., Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab. Dispos. 1997, 25, 1045-1050.
92. Arimori, K., Kuroki, N., Hidaka, M., Iwakiri, T. et al., Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm. Res. 2003, 20, 910-917.
93. Mohamed, M. E., Tseng, T., Frye, R. F., Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. Xenobiotica 2010, 40, 663-669.
94. Revesz, K., Tutto, A., Margittai, E., Banhegyi, G. et al., Glucuronide transport across the endoplasmic reticulum membrane is inhibited by epigallocatechin gallate and other green tea polyphenols. Int. J. Biochem. Cell Biol. 2007, 39, 922-930.
95. Fujita, K., Sparreboom, A., Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr. Clin. Pharmacol. 2010, 5, 209-217.
96. Fujita, K., Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol. Drug Interact. 2004, 20, 195-217.
97. Harris, R. Z., Jang, G. R., Tsunoda, S., Dietary effects on drug metabolism and transport. Clin. Pharmacokinet. 2003, 42, 1071-1088.
98. Engdal, S., Nilsen, O. G., In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother. Res. 2009, 23, 906-912.
99. Wanwimolruk, S., Wong, K., Wanwimolruk, P., Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4. Drug Metabol. Drug Interact. 2009, 24, 17-35.
100. Nishikawa, M., Ariyoshi, N., Kotani, A., Ishii, I. et al., Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab. Pharmacokinet. 2004, 19, 280-289.
101. Zou, L., Harkey, M. R., Henderson, G. L., Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002, 71, 1579-1589.
102. Muto, S., Fujita, K., Yamazaki, Y., Kamataki, T., Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat. Res. 2001, 479, 197-206.
103. Gullett, N. P., Ruhul Amin, A. R., Bayraktar, S., Pezzuto, J. M. et al., Cancer prevention with natural compounds. Semin. Oncol. 2010, 37, 258-281.
104. Mukhtar, H., Ahmad, N., Green tea in chemoprevention of cancer. Toxicol. Sci. 1999, 52, 111-117.
105. Obermeier, M. T., White, R. E., Yang, C. S., Effects of bioflavonoids on hepatic P450 activities. Xenobiotica 1995, 25, 575-584.
106. Niwattisaiwong, N., Luo, X. X., Coville, P. F., Wanwimolruk, S., Effects of Chinese, Japanese and Western tea on hepatic P450 enzyme activities in rats. Drug Metabol. Drug Interact. 2004, 20, 43-56.
107. Maliakal, P. P., Wanwimolruk, S., Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J. Pharm. Pharmacol. 2001, 53, 1323-1329.
108. Jang, E. H., Choi, J. Y., Park, C. S., Lee, S. K. et al., Effects of green tea extract administration on the pharmacokinetics of clozapine in rats. J. Pharm. Pharmacol. 2005, 57, 311-316.
109. Chow, H. H., Hakim, I. A., Vining, D. R., Crowell, J. A. et al., Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 2473-2476.
110. Donovan, J. L., Chavin, K. D., Devane, C. L., Taylor, R. M. et al., Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab. Dispos. 2004, 32, 906-908.
111. Golden, E. B., Lam, P. Y., Kardosh, A., Gaffney, K. J. et al., Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113, 5927-5937.
112. Adams, J., Kauffman, M., Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004, 22, 304-311.
113. Ge, J., Tan, B.-J., Chen, Y., Yang, L. et al., Interaction of green tea poly-phenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J. Mol. Med. 2011, in press, DOI: 10.1007/s00109-011-0737-3.
114. Heng, D. Y., Kollmannsberger, C., Sunitinib. Recent Results Cancer Res. 2010, 184, 71-82.
115. Long, L. H., Kirkland, D., Whitwell, J., Halliwell, B., Different cytotoxic and clastogenic effects of epigallocatechin gallate in various cell-culture media due to variable rates of its oxidation in the culture medium. Mutat. Res. 2007, 634, 177-183.
116. Wang, P., Henning, S. M., Heber, D., Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 2010, 5, e10202.
117. Boeseken, J., The use of boric acid for the determination of the configuration of carbohydrates. Adv. Carbohydr. Chem. 1949, 4, 189-210.
118. Lorand, J. P., Edwards, J. O., Polyol complexes and structure of the benzeneboronate ion. J. Org. Chem. 1959, 24, 769-774.
119. Springsteen, G., Wang, B. A., Detailed examination of boronic acid-diol complexation. Tetrahedron 2002, 58, 5291-5300.
120. Ghosh, N., Emadi, A., From orbital hybridization to chemotherapeutics neutralization. Blood 2009, 113, 6262.
121. Barnes, P. M., Powell-Griner, E., Complementary and alternative medicine use among adults: United States, 2002. Advance Data from Vital and Health Statistics, vol. 343, 2004. U.S. Department of Health and Human Services, National Center for Health Statistics Hyattsville, MD 2004.
122. Lambert, J. D., Kwon, S. J., Ju, J., Bose, M. et al., Effect of genistein on the bioavailability and intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate. Carcinogenesis 2008, 29, 2019-2024.
123. Fu, H., He, J., Mei, F., Zhang, Q. et al., Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E). Cancer Prev. Res. (Phila) 2009, 2, 531-537.
124. Yan, Y., Cook, J., McQuillan, J., Zhang, G. et al., Chemopreventive effect of aerosolized polyphenon E on lung tumorigenesis in A/J mice. Neoplasia 2007, 9, 401-405.
125. Suganuma, M., Okabe, S., Kai, Y., Sueoka, N. et al., Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res. 1999, 59, 44-47.
126. Shimizu, M., Deguchi, A., Lim, J. T., Moriwaki, H. et al., (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin. Cancer Res. 2005, 11, 2735-2746.
127. Mancuso, C., Barone, E., Therapeutic use of tea derivatives: all that glitters is not gold. Blood 2009, 114, 2359-2360.
128. USP to Defer Decision on Green Tea Extract Cautionary Labeling. 2008, .
129. Lambert, J. D., Sang, S., Yang, C. S., Possible controversy over dietary polyphenols: benefits vs risks. Chem. Res. Toxicol. 2007, 20, 583-585.